A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor Types
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
A putative tumor suppressor locus on the short arm of human chromosome 9 has been localized to a region of less than 40 kilobases by means of homozygous deletions in melanoma cell lines. This region contained a gene, Multiple Tumor Suppressor 1 (MTS1), that encodes a previously identified inhibitor (p16) of cyclin-dependent kinase 4. MTS1 was homozygously deleted at high frequency in cell lines derived from tumors of lung, breast, brain, bone, skin, bladder, kidney, ovary, and lymphocyte. Melanoma cell lines that carried at least one copy of MTS1 frequently carried nonsense, missense, or frameshift mutations in the gene. These findings suggest that MTS1 mutations are involved in tumor formation in a wide range of tissues.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Within months of its discovery, the INK4a (CDKN2A) and the genetically linked INK4b gene (CDKN2B) (36) were implicated in a reverse genetic screen to play tumor suppressive roles in familial melanoma (37).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [37]
Citations
Cites
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
A novel cyclin encoded by a bcl1-linked candidate oncogene
Motokura, T., Bloom, T., Kim, H. G., Jüppner., H., Ruderman, J. V., Kronenberg, H. M., & Arnold, A. (1991) · Nature · doi:10.1038/350512a0 · Cited by 1,265
Functional interactions of the retinoblastoma protein with mammalian D-type cyclins
Ewen, M. E., Sluss, H. K., Sherr, C. J., Matsushime, H., Kato, J.-Y., & Livingston, D. M. (1993) · Cell · doi:10.1016/0092-8674(93)90136-e · Cited by 1,010
Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit
Gu, Y., Turck, C. W., & Morgan, D. O. (1993) · Nature · doi:10.1038/366707a0 · Cited by 764
p53: At the Crossroads of Molecular Carcinogenesis and Risk Sssessment
Harris, C. C. (1993) · Science · doi:10.1126/science.8266092 · Cited by 475
PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma.
Rosenberg, C. L., Wong, E., Petty, E. M., Bale, A. E., Tsujimoto, Y., Harris, N. L., & Arnold, A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.21.9638 · Cited by 432
Research works printed but not linked: 1
- Weaver-Feldhaus, J., Proceedings of the National Academy of Sciences of the United States of America 91: 7563 (1994).
Cited by
Items 501–600 of 1,005
p27KIP1 in human lung cancers: differential changes in small cell and non-small cell carcinomas.
Yatabe, Y., Masuda, A., Koshikawa, T., Nakamura, S., Kuroishi, T., Osada, H., Takahashi, T., Mitsudomi, T., & Takahashi, T. (1998) · PubMed · Cited by 111
Ogawa, S., Hangaishi, A., Miyawaki, S., Hirosawa, S., Miura, Y., Takeyama, K., Kamada, N., Ohtake, S., Uike, N., & Shimazaki, C. (1995) · Blood · doi:10.1182/blood.v86.4.1548.bloodjournal8641548 · Cited by 107
Anticancer Effect of Thymol on AGS Human Gastric Carcinoma Cells
Kang, S.-H., Kim, Y.-S., Kim, E., Hwang, J.-W., Jeong, J.-H., Dong, X., Lee, J. W., Moon, S.-H., Jeon, B.-T., & Park, P. (2016) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1506.06073 · Cited by 109
Cellular senescence and its role in white adipose tissue
Smith, U., Li, Q., Rydén, M., & Spalding, K. L. (2021) · International Journal of Obesity · doi:10.1038/s41366-021-00757-x · Cited by 122
Kees, U. R., Burton, P. R., Lü, C., & Baker, D. L. (1997) · Blood · doi:10.1182/blood.v89.11.4161 · Cited by 109
Gorgoulis, V. G., Zacharatos, P., Kotsinas, A., Liloglou, T., Kyroudi, A., Veslemes, M., Rassidakis, A., Halazonetis, T. D., Field, J. K., & Kittas, C. N. (1998) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65690-8 · Cited by 113
Takino, H., Li, C., Hu, S., Kuo, T., Geissinger, E., Müller‐Hermelink, H. K., Kim, B.-C., Swerdlow, S. H., & Inagaki, H. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.159 · Cited by 103
Uveal melanoma in young patients.
Singh, A. D., Shields, C. L., Shields, J. A., & Sato, T. (2000) · PubMed · Cited by 118
Tumor Progression, Early Diagnosis and Prognosis of Melanoma
Elder, D. E. (1999) · Acta Oncologica · doi:10.1080/028418699431113 · Cited by 111
Aagaard, L., Lukas, J., Bartkova, J., Kjerulff, A., Strauss, M., & Bartek, J. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910610120 · Cited by 102
Maelandsmo, G., Berner, J.-M., Flørenes, V., Forus, A., Hovig, E., Fodstad, Ø., & Myklebost, O. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.344 · Cited by 102
Simoneau, M., Aboulkassim, T., LaRue, H., Rousseau, F., & Fradet, Y. (1999) · Oncogene · doi:10.1038/sj.onc.1202277 · Cited by 115
“Another tumor suppressor gene, p15 (also described as INK4B or MTS2), has been also identi®ed in this region and deletions of this gene occur frequently in cancer cell lines and in certain malignancies (Kamb et al., 1994; Shapiro and Rollins, 1996).”
BackgroundDeletions and rearrangement of CDKN2 in lymphoid malignancy
Stranks, G., Height, S., Mitchell, P. L. R., Jadayel, D. M., Ma, Y., Lord, C., Clutterbuck, R. D., Treleaven, J., Powles, R. L., & Nacheva, E. P. (1995) · Blood · doi:10.1182/blood.v85.4.893.bloodjournal854893 · Cited by 107
Inherited Genetic Susceptibility to Breast Cancer
Ghoussaini, M., Pharoah, P. D. P., & Easton, D. F. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.07.003 · Cited by 123
A survey of homozygous deletions in human cancer genomes
Cox, C., Bignell, G., Greenman, C., Stabenau, A., Warren, W., Stephens, P., Davies, H., Watt, S., Teague, J., Edkins, S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408593102 · Cited by 100
Breast cancer epigenetics: normal human mammary epithelial cells as a model system
Hinshelwood, R. A., & Clark, S. J. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0386-3 · Cited by 116
“Cell cycle control by this pathway is often lost in human cancer, typically by disruption of p16 function via deletion [52], point mutations [52], or promoter hypermethylation [53].”
BackgroundSoberanes, S., Gonzalez, A., Urich, D., Chiarella, S. E., Radigan, K. A., Osornio-Vargas, Á. R., Joseph, J., Kalyanaraman, B., Ridge, K. M., Chandel, N. S., et al. (2012) · Scientific Reports · doi:10.1038/srep00275 · Cited by 114
“Lung cancer is associated with several characteristic epigenetic changes; one of the most common is the methylation of the promoter for the tumor suppressor p16, which has been reported in >70% cell lines derived human non-small cell lung cancer”
BackgroundRole of pRB dephosphorylation in cell cycle regulation
Tamrakar, S. (2000) · Frontiers in Bioscience · doi:10.2741/tamrakar · Cited by 101
Alterations of the p15, p16, and p18 genes in osteosarcoma
Miller, C. W., Aslo, A., Campbell, M. J., Kawamata, N., Lampkin, B. C., & Koeffler, H. P. (1996) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(95)00216-2 · Cited by 116
Differential CDK-inhibitor gene expression in aging human diploid fibroblasts
Wong, H., & Riabowol, K. T. (1996) · Experimental Gerontology · doi:10.1016/0531-5565(95)00025-9 · Cited by 114
Identification of CDK4 Sequences Involved in Cyclin D1 and p16 Binding
Coleman, K. G., Wautlet, B. S., Morrissey, D., Mulheron, J., Sedman, S. A., Brinkley, P., Price, S., & Webster, K. R. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.30.18869 · Cited by 100
Haploinsufficiency of p18INK4c Sensitizes Mice to Carcinogen-Induced Tumorigenesis
Bai, F., Pei, X.-H., Godfrey, V. L., & Xiong, Y. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.4.1269-1277.2003 · Cited by 100
Kudo, Y., Takata, T., Ogawa, I., Kaneda, T., Sato, S., Takekoshi, T., Zhao, M., Miyauchi, M., & Nikai, H. (2000) · PubMed · Cited by 108
Clark, J., Edwards, S. E., Feber, A., Flohr, P., John, M. M., Giddings, I., Crossland, S., Stratton, M. R., Wooster, R., Campbell, C., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206247 · Cited by 105
“Indeed, most of these suppressor genes (DPC4/SMAD4, RB1, PTEN, p16INK4a) were originally pinpointed through mapping regions of complete loss in cancer cells (Friend et al., 1986; Kamb et al., 1994; Hahn et al., 1996; Li et al., 1997).”
BackgroundCurrent Concepts in Neuro-Oncology: The Cell Cycle-A Review
Dirks, P. B., & Rutka, J. T. (1997) · Neurosurgery · doi:10.1097/00006123-199705000-00025 · Cited by 115
The Molecular Epidemiology of Lung Cancer
Spivack, S. D., Fasco, M. J., Walker, V. E., & Kaminsky, L. S. (1997) · Critical Reviews in Toxicology · doi:10.3109/10408449709089898 · Cited by 96
McKenna, D. B., Stockton, D., Brewster, D., & Doherty, V. R. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600692 · Cited by 99
“The p16 gene, which inhibits the cyclin-dependent kinase CDNK4, has been proposed as a candidate for a tumour suppressor gene located on chromosome 9p21 (Kamb et al, 1994).”
BackgroundBodner‐Adler, B., Bodner, K., Czerwenka, K. F., Kimberger, O., Leodolter, S., & Mayerhofer, K. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.09.026 · Cited by 99
Ikuta, M., Kamata, K., Fukasawa, K., Honma, T., Machida, T., Hirai, H., Suzuki-Takahashi, I., Hayama, T., & Nishimura, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102060200 · Cited by 99
Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells.
Satyamoorthy, K., Chehab, N. H., Waterman, M. J. F., Lien, M. C., El‐Deiry, W. S., Herlyn, M., & Halazonetis, T. D. (2000) · PubMed · Cited by 114
Role of Cyclin-Dependent Kinases and Their Inhibitors in Cellular Differentiation and Development
Chellappan, S., Giordano, A., & Fisher, P. B. (1998) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-71941-7_4 · Cited by 102
p16INK4a Gene Alterations Are Frequent in Lesions of Mycosis Fungoides
Navas, I. C., Ortiz-Romero, P. L., Villuendas, R., Martínez, P., García, C., Gómez, E., Rodriguez, J. L., García, D., Vanaclocha, F., Iglesias, L., et al. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65028-6 · Cited by 107
Radford, K. J., Mallesch, J., & Mersey, P. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910620523 · Cited by 98
TEL and KIP1 define the smallest region of deletions on 12p13 in hematopoietic malignancies
Sato, Y., Suto, Y., Pietenpol, J. A., Golub, T. R., Gilliland, D. G., Em, D., Beau, M. M. L., Roberts, J., Vogelstein, B., & Rowley, J. (1995) · Blood · doi:10.1182/blood.v86.4.1525.bloodjournal8641525 · Cited by 109
p16 and p16 beta are potent growth suppressors of head and neck squamous carcinoma cells in vitro.
Liggett, W. H., Sewell, D. A., Rocco, J., Ahrendt, S. A., Koch, W. M., & Sidransky, D. (1996) · PubMed · Cited by 114
A genetic model of melanoma tumorigenesis based on allelic losses
Walker, G. J., Palmer, J. M., Walters, M. K., & Hayward, N. K. (1995) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870120208 · Cited by 103
Mettus, R. V., & Rane, S. G. (2003) · Oncogene · doi:10.1038/sj.onc.1206888 · Cited by 97
“Among these proteins, p16INK4a appears to play a critical role in regulating cell proliferation, since it is either mutated or deleted in a significant number of human tumors (Kamb et al., 1994; Nobori et al., 1994).”
BackgroundEmig, R., Magener, A., Ehemann, V, Meyer, A., Stilgenbauer, F., Volkmann, M., Wallwiener, D., & Sinn, H. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.739 · Cited by 97
The molecular biology of oral carcinogenesis: Toward a tumor progression model
Todd, R., Donoff, R. B., & Wong, D. T. (1997) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/s0278-2391(97)90495-x · Cited by 128
Arresting developments in the cardiac myocyte cell cycle: Role of cyclin-dependent kinase inhibitors
Brooks, G., Poolman, R. A., & Li, J. M. (1998) · Cardiovascular Research · doi:10.1016/s0008-6363(98)00125-4 · Cited by 113
Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors
Ibrahim, D. A., & Elmetwally, A. M. (2009) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2009.12.026 · Cited by 101
MDM2 and CDK4 gene amplification in Ewing's sarcoma
Ladanyi, M., Lewis, R., Jhanwar, S. C., Gerald, W., Huvos, A. G., & Healey, J. H. (1995) · The Journal of Pathology · doi:10.1002/path.1711750209 · Cited by 98
Loss of heterozygosity in sporadic primary cutaneous melanoma
Healy, E., Rehman, I., Angus, B., & Rees, J. L. (1995) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870120211 · Cited by 105
Zhu, G., Conner, S. E., Zhou, X., Shih, C., Li, T., Anderson, B. D., Brooks, H. B., Campbell, R. M., Considine, E., Dempsey, J. A., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0256169 · Cited by 96
Haruki, S., Imoto, I., Kozaki, K., Matsui, T., Kawachi, H., Komatsu, S., Muramatsu, T., Shimada, Y., Kawano, T., & Inazawa, J. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq053 · Cited by 96
Amplification of 19q13.1–q13.2 sequences in ovarian cancer
Thompson, F. H., Nelson, M. A., Trent, J. M., Guan, X., Liu, Y., Yang, J.-M., Emerson, J., Adair, L., Wymer, J. A., Balfour, C. A., et al. (1996) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(95)00248-0 · Cited by 96
Kim, K. S., Sack, J. S., Tokarski, J. S., Qian, L., Chao, S. T., Leith, L. W., Kelly, Y. F., Misra, R. N., Hunt, J. T., Kimball, S. D., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000231g · Cited by 104
Molecular foundations of cancer: New targets for intervention
Karp, J. E., & Broder, S. E. (1995) · Nature Medicine · doi:10.1038/nm0495-309 · Cited by 112
Representational difference analysis: finding the differences between genomes
Lisitsyn, N. A. (1995) · Trends in Genetics · doi:10.1016/s0168-9525(00)89087-3 · Cited by 96
Isolation of differentially expressed sequence tags from human breast cancer.
Watson, M. A., & Fleming, T. P. (1994) · PubMed · Cited by 95
Alteration of p16 and p15 genes in human uterine tumours
Nakashima, R., Fujita, M., Enomoto, T., Haba, T., Yoshino, K., Wada, H., Kurachi, H., Sasaki, M., Wakasa, K., Inoue, M., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690379 · Cited by 105
“A cDNA aliquot corresponding to 200–500 ng of RNA w used as the template for polymerase chain reaction (PCR) am cation.”
BackgroundMethodInfluentialTumor suppressor genes and medulloblastoma
Cogen, P. H., & McDonald, J. D. (1996) · Journal of Neuro-Oncology · doi:10.1007/bf00165523 · Cited by 95
“Experimental studies have resulted in the cloning of one of the genes for Wilm's tumor, a common pediatric renal malignancy (Wtl, located on chromosome 11) [17], several of the genes that function in the neoplastic cascade resulting in colorectal cancer, including the gene for familial adenomatous polyposis (FAR locat…”
BackgroundSakorafas, G. H., Tsiotou, A. G., & Tsiotos, G. G. (2000) · Cancer Treatment Reviews · doi:10.1053/ctrv.1999.0144 · Cited by 103
Thymol inhibits bladder cancer cell proliferation via inducing cell cycle arrest and apoptosis
Li, Y., Wen, J., Du, C., Hu, S., Chen, J., Zhang, S., Zhang, N., Gao, F., Li, S.-J., Mao, X.-W., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.04.009 · Cited by 105
FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma
Chung, C. T.-S., Santos, G. D. C., Hwang, D. M., Ludkovski, O., Pintilie, M., Squire, J. A., & Tsao, M.-S. (2010) · Journal of Clinical Pathology · doi:10.1136/jcp.2010.076794 · Cited by 95
Alterations of pRb1-cyclin D1-cdk4/6-p16INK4A pathway in endometrial carcinogenesis
Semczuk, A., & Jakowicki, J. A. (2003) · Cancer Letters · doi:10.1016/j.canlet.2003.09.012 · Cited by 104
Cytokines and tumors of the central nervous system
Meir, E. G. V. (1995) · Glia · doi:10.1002/glia.440150308 · Cited by 97
Cayuela, J., Madani, A., Sanhes, L., Stern, M., & Sigaux, F. (1996) · Blood · doi:10.1182/blood.v87.6.2180.bloodjournal8762180 · Cited by 94
Defective expression of polarity protein PAR-3 gene (PARD3) in esophageal squamous cell carcinoma
Zen, K., Yasui, K., Gen, Y., Dohi, O., Wakabayashi, N., Mitsufuji, S., Itoh, Y., Zen, Y., Nakanuma, Y., Taniwaki, M., et al. (2009) · Oncogene · doi:10.1038/onc.2009.148 · Cited by 101
“Suppressor genes that have been identified partly from homozygous deletions include CDKN2A (Kamb et al., 1994), PTEN (Li et al., 1997) and SMAD4 (Hahn et al., 1996).”
BackgroundTreatment of BRAF-Mutant Melanoma: The Role of Vemurafenib and Other Therapies
Jang, S., & Atkins, M. B. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.197 · Cited by 103
MOZ (MYST3, KAT6A) inhibits senescence via the INK4A-ARF pathway
Sheikh, B. N., Phipson, B., El-Saafin, F., Vanyai, H. K., Downer, N. L., Bird, M., Kueh, A. J., May, R. E., Smyth, G. K., Voss, A. K., et al. (2015) · Oncogene · doi:10.1038/onc.2015.33 · Cited by 98
Yamada, H., Yanagisawa, K., Tokumaru, S., Taguchi, A., Nimura, Y., Osada, H., Nagino, M., & Takahashi, T. (2008) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20582 · Cited by 97
“…and tumor suppressor genes including RB1, WT1, CDKN2A, BRCA2, SMAD4, and PTEN/MMAC1 have been identified in homozygous deletion regions (Friend et al., 1986; Call et al., 1990; Kamb et al., 1994; Nobori et al., 1994; Wooster et al., 1995; Hahn et al., 1996; Li et al., 1997; Steck et al., 1997).”
BackgroundHuynh, H. T., Chow, P. K. H., Ooi, L. L., & Soo, K. C. (2002) · PubMed · Cited by 92
Klangby, U., Okan, İ., Magnússon, K. P., Wendland, M., Lind, P., & Wiman, K. G. (1998) · Blood · doi:10.1182/blood.v91.5.1680 · Cited by 106
Zhang, W., Kornblau, S. M., Kobayashi, T., Gambel, A. M., Claxton, D. F., & Deisseroth, A. B. (1995) · PubMed · Cited by 107
Taniai, M., Higuchi, H., Burgart, L. J., & Gores, G. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.36021 · Cited by 99
Funk, J. O., Schiller, P. I., Barrett, M. T., Wong, D. J., Kind, P., & Sander, C. A. (1998) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.1998.tb01748.x · Cited by 104
Paige, A. J. W., Taylor, K. J., Stewart, A., SGOUROS, J. G., Gabra, H., Sellar, G., Smyth, J. F., Porteous, D. J., & Watson, J. E. V. (2000) · PubMed · Cited by 111
Temperature-Sensitive Mutants of p16CDKN2 Associated with Familial Melanoma
Parry, D., & Peters, G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.7.3844 · Cited by 94
Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines
Sartor, M., Steingrimsdottir, H., Elamin, F., Gäken, J. A., Warnakulasuriya, S., Partridge, M., Thakker, N., Johnson, N. W., & Tavassoli, M. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690505 · Cited by 103
BRAF Point Mutations in Primary Melanoma Show Different Prevalences by Subtype
Sasaki, Y., Niu, C., Makino, R., Kudo, C., Sun, C., Watanabe, H. K., Matsunaga, J., Takahashi, K., Tagami, H., Aiba, S., et al. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.22722.x · Cited by 91
Kuo, K., Hsiao, C.-H., Lin, C., Kuo, L., Huang, S., & Lin, M.-C. (2008) · Modern Pathology · doi:10.1038/modpathol.3800979 · Cited by 92
Dai, C. Y., Furth, E. E., Mick, R., Koh, J., Takayama, T., Niitsu, Y., & Enders, G. H. (2000) · Gastroenterology · doi:10.1053/gast.2000.17952 · Cited by 92
Tsuda, H., YAMAMOTO, K., Inoue, T., Uchiyama, I., & Umesaki, N. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.0980 · Cited by 95
Comparative Histopathology of Grey‐Horse‐Melanoma and Human Malignant Melanoma
Seltenhammer, M. H., Heere‐Ress, E., Brandt, S., Druml, T., Jansen, B., Pehamberger, H., & NIEBAUER, G. W. (2004) · Pigment Cell Research · doi:10.1111/j.1600-0749.2004.00192.x · Cited by 91
Alterations in the INK4a/ARF locus and their effects on the growth of human osteosarcoma cell lines
Park, Y.-B., Park, M. J., Kimura, K., Shimizu, K., Lee, S. H., & Yokota, J. (2002) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(01)00575-1 · Cited by 100
Wiest, J. S., Franklin, W. A., Otstot, J., Forbey, K. C., Varella‐Garcia, M., Rao, K., Drabkin, H. A., Gemmill, R. M., Ahrent, S., Sidransky, D., et al. (1997) · PubMed · Cited by 91
Dosaka‐Akita, H., Hu, S., Fujino, M., Harada, M., Kinoshita, I., Xu, H., Kuzumaki, N., Kawakami, Y., & Benedict, W. F. (1997) · PubMed · Cited by 91
Ordulu, Z., Nucci, M. R., Cin, P. D., Hollowell, M. L., Otis, C. N., Hornick, J. L., Park, P. J., Kim, T., Quade, B. J., & Morton, C. C. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.36 · Cited by 90
THE MOLECULAR CHARACTERISTICS OF BLADDER CANCER IN YOUNG PATIENTS
Linn, J. F., Sesterhenn, I. A., Mostofi, F. K., & Schoenberg, M. (1998) · The Journal of Urology · doi:10.1097/00005392-199805000-00022 · Cited by 90
Update on familial cancer syndromes and the skin
Tsao, H. (2000) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2000.104681 · Cited by 98
White, R. L., Schwartzentruber, D. J., Guleria, A. S., Macfarlane, M., White, D. E., Tucker, E. E., & Rosenberg, S. A. (1994) · Cancer · doi:10.1002/1097-0142(19941215)74:12<3135::aid-cncr2820741212>3.0.co;2-8 · Cited by 108
Expression of the Tumor Suppressor Gene Product p16INK4 in Benign and Malignant Melanocytic Lesions
Keller‐Melchior, R., Schmidt, R. A., & Piepkorn, M. W. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00211.x · Cited by 96
“Subsequently, observations of segregating germline mutations in melanoma kindreds (Hussussian et al, 1994; Kamb et al, 1994b) and of somatic mutations in tumor cell lines of multiple histogenetic lineages (Smith-Sørensen and Hovig, 1996) have strongly supported the candidacy of MTS1 as a…”
BackgroundRegulation and activation of p53 and its family members
Lohrum, M. A. E., & Vousden, K. H. (1999) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400625 · Cited by 102
Ritland, S. R., Ganju, V., & Jenkins, R. B. (1995) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870120407 · Cited by 90
Reichert, T. E., Scheuer, C., Day, R., Wagner, W., & Whiteside, T. L. (2001) · Cancer · doi:10.1002/1097-0142(20010601)91:11<2136::aid-cncr1242>3.0.co;2-q · Cited by 162
Sequential Unfolding of Ankyrin Repeats in Tumor Suppressor p16
Tang, K. S., Fersht, A. R., & Itzhaki, L. S. (2003) · Structure · doi:10.1016/s0969-2126(02)00929-2 · Cited by 105
Genetic mechanisms in squamous cell carcinoma of the head and neck
Jefferies, S., & Foulkes, W. D. (2001) · Oral Oncology · doi:10.1016/s1368-8375(00)00065-8 · Cited by 89
van Beerendonk, H. M., Rozeman, L. B., Taminiau, A. H. M., Sciot, R., Bovée, J. V. M. G., Cleton-Jansen, A., & Hogendoorn, P. C. W. (2004) · The Journal of Pathology · doi:10.1002/path.1517 · Cited by 92
Arendt, T. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00216-5 · Cited by 97
Venkataramani, R. N., Swaminathan, K., & Marmorstein, R. (1998) · Nature Structural Biology · doi:10.1038/nsb0198-74 · Cited by 89
Tumour suppressor genes in disease and therapy
Skuse, G. R., & Ludlow, J. W. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90015-2 · Cited by 88
p16 promoter hypermethylation: A useful serum marker for early detection of gastric cancer
Abbaszadegan, M. R., Moaven, O., Sima, H. R., Ghafarzadegan, K., Arabi, A., Forghani, M. N., Raziee, H., Mashhadinejad, A., Jafarzadeh, M., Shandiz, E. E., et al. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.2055 · Cited by 88
Björkqvist, A.-M., Tammilehto, L., Anttila, S. L., Mattson, K. V., & Knuutila, S. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.91 · Cited by 88
Vo, Q. N., Geradts, J., Gulley, M. L., Boudreau, D. A., Bravo, J. C., & Schneider, B. (2002) · Journal of Clinical Pathology · doi:10.1136/jcp.55.9.669 · Cited by 88
Allelotype of endometrial carcinoma.
Fujino, T., Risinger, J. I., Collins, N. K., Liu, F.-S., Nishii, H., Takahashi, H., Westphal, E., Barrett, J. C., Sasaki, H., & Kohler, M. F. (1994) · PubMed · Cited by 94
Negative regulation of cell growth by TGFβ
Polyák, K. (1996) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(95)00009-5 · Cited by 107
Rattan, S. I. S. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06655.x · Cited by 91
Cdt1 transgenic mice develop lymphoblastic lymphoma in the absence of p53
Seo, J., Chung, Y. S., Sharma, G. G., Moon, E., Burack, W. R., Pandita, T. K., & Choi, K. (2005) · Oncogene · doi:10.1038/sj.onc.1208881 · Cited by 102
“Examples include overexpression of cyclinD1 in many cancers (Motokura et al., 1991) and inactivating mutations of INK4a in biliary tract and esophageal carcinomas as well as familial melanoma (Kamb et al., 1994; Nobori et al., 1994).”
BackgroundFuxe, J., Akusjärvi, G., Goike, H. M., Roos, G., Collins, V. P., & Pettersson, R. F. (2000) · PubMed · Cited by 99
Metadata
- Authors
- Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H.
- Affiliations
- Myriad Genetics (US)
- Memorial Sloan Kettering Cancer Center (US)
- Cross Cancer Institute (CA)
- National Institutes of Health (US)
- University of Utah (US)
- Venue
- Science
- Published
- 1994-04-15
- Volume
- 264
- Issue
- 5157
- Pages
- 436-440
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1983348452
- Cited by
- 2,751
- References
- 26
- Citations by year
- 2026: 11 · 2025: 8 · 2024: 18 · 2023: 12 · 2022: 22 · 2021: 31 · 2020: 24 · 2019: 23 · 2018: 34 · 2017: 45 · 2016: 20 · 2015: 32 · 2014: 31 · 2013: 44 · 2012: 54
- FWCI
- 115.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p01ca048711-05)
- National Cancer Institute (CA 48711)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- CDKN2A, p16, tumor suppressor, chromosome 9p, homozygous deletion, melanoma cell lines, CDK4, cell cycle regulation, genetic mutations
- MeSH terms
- Base Sequence, Carrier Proteins, Cell Cycle, Chromosomes, Human, Pair 9, Cosmids, Exons, Humans, Introns, Melanoma, Molecular Sequence Data, Mutation, Neoplasms, Proto-Oncogene Proteins, Tumor Cells, Cultured, Genes, Tumor Suppressor, Gene Deletion, Cyclin-Dependent Kinases, Cyclin-Dependent Kinase Inhibitor p16, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.